Associate Medical Director for Inpatient Services, Harbor-UCLA Medical Center
Internal Medicine
Dr. Brad Spellberg, MD
|
|
Give Review
Brad Spellberg works in the field of Internal Medicine. He studied medicine at David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a top medical university. David Geffen School of Medicine at UCLA is ranked 13/7 in Research/PrimaryCare. Brad Spellberg is a published physician as well. He has 99 publications published. The latest was: Novel antipsychotics and new onset diabetes.
Publications
- New Societal Approaches to Empowering Antibiotic Stewardship.
- Important Complexities of the Antivirulence Target Paradigm: a Novel Ostensibly Resistance-Avoiding Approach for Treating Infections.
- Non-Inferiority Doesn't Mean Not Inferior.
- Novel approaches are needed to develop tomorrow's antibacterial therapies.
- A Simple Intervention to Improve Hospital Flow From Emergency Department to Inpatient Units.
- Host Fate Is Rapidly Determined by Innate Effector-Microbial Interactions During Acinetobacter baumannii Bacteremia.
- The future of antibiotics and resistance: a tribute to a career of leadership by john bartlett.
- Does real-time feedback to residents with or without attendings improve medical documentation?
- Different tumor necrosis factor α antagonists have different effects on host susceptibility to disseminated and oropharyngeal candidiasis in mice.
- Volume of fluids administered during resuscitation for severe sepsis and septic shock and the development of the acute respiratory distress syndrome.
- The Deadly Impact of Extreme Drug Resistance in Acinetobacter baumannii*.
- Staphylococcus aureus Bacteremia at Five U.S. Academic Medical Centers, 2008-2011: Significant Geographic Variation in Community-Onset Infections.
- Antibacterial Resistance Leadership Group: Open for Business.
- Antibiotic judo: working gently with prescriber psychology to overcome inappropriate use.
- Transferrin iron starvation therapy for lethal bacterial and fungal infections.
- The value of single-pathogen antibacterial agents.
- Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.
- "Airborne Assault": A New Dimension in Acinetobacter baumannii Transmission*.
- Impact of Hospital Variables on Case Mix Index as a Marker of Disease Severity.
- Seven Ways to Preserve the Miracle of Antibiotics.
- The future of antibiotics and resistance.
- Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.
- Diabetic murine models for Acinetobacter baumannii infection.
- A controlled investigation of optimal internal medicine ward team structure at a teaching hospital.
- Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin.
- Risk factors for mortality in patients with mucormycosis.
- Gastrointestinal mucormycosis: an evolving disease.
- Reduced virulence of Candida albicans PHR1 mutants.
- Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole.
- Candida albicans stimulates cytokine production and leukocyte adhesion molecule expression by endothelial cells.
- Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy.
- Cloning and characterization of CAD1/AAF1, a gene from Candida albicans that induces adherence to endothelial cells after expression in Saccharomyces cerevisiae.
- Olanzapine-induced reversible priaprism: a case report.
- Novel antipsychotics and new onset diabetes.
- Mechanism of intravenous immune globulin therapy.
- Autologous bone marrow transplantation in acute leukemia.
- The cutaneous citadel: a holistic view of skin and immunity.
- Type 1/Type 2 immunity in infectious diseases.
- mtDNA disease in the primary care setting.
- Lack of cross-hepatotoxicity between fluconazole and voriconazole.
- Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis.
- Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.
- Amphotericin B: is a lipid-formulation gold standard feasible?
- Trends in antimicrobial drug development: implications for the future.
- Readmissions at a public safety net hospital.
- Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene.
- Treatment of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections with drainage but no antibiotic therapy.
- Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6.
- Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro.
- Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.
- Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dos...
- Cryopreservation of virulent Acinetobacter baumannii to reduce variability of in vivo studies.
- Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice.
- Spider bites and infections caused by community-associated methicillin-resistant Staphylococcus aureus.
- Ly6G-mediated depletion of neutrophils is dependent on macrophages.
- Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles.
- Is computed tomography of the head useful before lumbar puncture?
- A phagocytic cell line markedly improves survival of infected neutropenic mice.
- Mice with disseminated candidiasis die of progressive sepsis.
- Novel perspectives on mucormycosis: pathophysiology, presentation, and management.
- The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocomprom...
- Current treatment strategies for disseminated candidiasis.
- Immunoglobulin G2 antibodies and HIV-infected long-term nonprogressors: what is the mechanism?
- The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis.
- Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis.
- Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.
- Deferiprone iron chelation as a novel therapy for experimental mucormycosis.
- Comparison of antifungal treatments for murine fusariosis.
- Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.
- Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts.
- Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S...
- Nosocomial fungal infections: epidemiology, diagnosis, and treatment.
- Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
- The iron chelator deferasirox protects mice from mucormycosis through iron starvation.
- Prospects for and barriers to a fungal vaccine.
- The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.
- Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans.
- Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.
- Combination echinocandin-polyene treatment of murine mucormycosis.
- Comparison of lipid amphotericin B preparations in treating murine zygomycosis.
- Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge.
- Antibiotic resistance and antibiotic development.
- Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity.
- Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.
- Dr. William H. Stewart: mistaken or maligned?
- The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus.
- Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis.
- Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?
- Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
- Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
- Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia.
- Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.
- Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
- Voriconazole use for endemic fungal infections.
- Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus.
- Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
- Recent advances in the management of mucormycosis: from bench to bedside.
- Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.
Schools
University of California At Los Angeles
Harbor UCLA
Doctors Specialties
- Infectious Disease Medicine
- Internal Medicine
Accepted Insurances
Education
-
Harbor - UCLA Medical Center -
David Geffen School of Medicine at UCLA
Hospital
-
Harbor-UCLA Medical Center -
Ronald Reagan UCLA Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Kasey K. Lai, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vincent Woo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary R. Doost, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emma B. Trejo, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Matthew Hakimi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David D. Rand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grace T. Kiet, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mallory D. Witt, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Eric N. Milefchik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert Deiss, MD |
|
|
Dr. Scott G. Filler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin M. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James A. McKinnell, MD
This Doctor is OpenDoctor Recommended.
|